Literature DB >> 9426423

Calciphylaxis in patients on hemodialysis: a prevalence study.

M Angelis1, L L Wong, S A Myers, L M Wong.   

Abstract

BACKGROUND: Calciphylaxis is characterized by painful, violaceous, mottled skin lesions (livedo reticularis) that may progress to tissue necrosis, nonhealing ulcers, gangrene, and potentially amputation, sepsis, or death. The prevalence and characteristics of patients who have calciphylaxis need further identification to predict which patients on dialysis may benefit from close monitoring or early surgical intervention.
METHODS: All 242 patients undergoing hemodialysis in an outpatient unit were reviewed retrospectively during a 15-month cross-sectional study of the prevalence and characteristics of calciphylaxis.
RESULTS: Ten patients (prevalence, 4.1%) had calciphylaxis. Patients with calciphylaxis were significantly younger (49 versus 60 years; p = 0.01), had undergone hemodialysis longer (80 versus 20 months; p < 0.0001), and had higher median serum calcium (9.7 versus 9.2 mg/dl; p = 0.03), phosphate (8.2 versus 5.7 mg/dl; p = 0.001), calcium phosphate product (81.5 versus 52.9; p = 0.0004), parathyroid hormone (1496 versus 138 pg/ml; p < 0.0001), and alkaline phosphatase levels (188 versus 89 IU/L; p = 0.0001). Bone surveys were positive in all 10 patients with calciphylaxis compared with 49 (21%) of the 232 patients without calciphylaxis (p < 0.0001). All patients who underwent parathyroidectomy for calciphylaxis had dramatic healing of the ulcers.
CONCLUSIONS: The presence of calciphylaxis is higher among younger patients who had undergone longer periods of hemodialysis. Therefore this group of patients should be monitored aggressively and treated expeditiously for complications of secondary hyperparathyroidism.

Entities:  

Mesh:

Year:  1997        PMID: 9426423     DOI: 10.1016/s0039-6060(97)90212-9

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  65 in total

1.  Chemical peritonitis after intraperitoneal sodium thiosulfate.

Authors:  D R Gupta; H Sangha; R Khanna
Journal:  Perit Dial Int       Date:  2012 Mar-Apr       Impact factor: 1.756

2.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

Review 3.  [Calciphylaxis. A call for interdisciplinary cooperation].

Authors:  V M Brandenburg; S Schmitz; J Floege; K Amann; M Ketteler
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

4.  A case report: radiological findings in an unusual case of calciphylaxis 16 years after renal transplantation.

Authors:  Sarahn Smith; Akimichi Inaba; Joseph Murphy; Gary Campbell; Andoni P Toms
Journal:  Skeletal Radiol       Date:  2013-06-11       Impact factor: 2.199

5.  Photoletter to the editor - Calciphylaxis: a diagnostic and therapeutic challenge.

Authors:  Hugo Marques Barreiros; João Goulão; Henriqueta Cunha; Elvira Bártolo
Journal:  J Dermatol Case Rep       Date:  2013-06-30

6.  Painful skin ulcers in a hemodialysis patient.

Authors:  Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

7.  Calciphylaxis: a severe complication of renal disease.

Authors:  Nina Scola; Alexander Kreuter
Journal:  CMAJ       Date:  2011-08-15       Impact factor: 8.262

Review 8.  Secondary and tertiary hyperparathyroidism, state of the art surgical management.

Authors:  Susan C Pitt; Rebecca S Sippel; Herbert Chen
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

9.  Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Authors:  Sagar U Nigwekar; Steven M Brunelli; Debra Meade; Weiling Wang; Jeffrey Hymes; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

10.  Surviving calciphylaxis.

Authors:  Paul Lee; Jacob Sevastos; Lesley V Campbell
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.